REGULATORY

• Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
  May 11, 2021

• Kanmin Taiwa Public-Private Confab Set for May 17
  May 11, 2021

• MHLW to Fund 7 Development Projects for COVID-19 Therapies
  May 11, 2021

• Japan in Talks with 3 Vaccine Makers for Additional Supplies, Eyes 250 Million More Doses
  May 10, 2021

• No Impact of Transport Seen on Comirnaty’s mRNA Content or Expression of Spike Proteins: NIHS Study
  May 10, 2021

• New Industry Vision to Reaffirm Pharmaceuticals as Growth Industry: MHLW Director
  April 30, 2021

• MHLW to Set New Generic Target of 80% in Every Prefecture by FY2023-End
  April 30, 2021

• LDP’s Project Team Calls for Audacious Gov’t Investment Targets for Drug Discovery Capabilities
  April 30, 2021

• MHLW Revokes Approval for 12 Kobayashi Kako Products, Imposes Biz Improvement Order
  April 30, 2021

• Bayer’s Heart Failure Med Now in Line for June Approval
  April 30, 2021

• Large-Scale Vaccination Center to Open in Tokyo on May 24
  April 28, 2021

• LDP Project Team Submits Proposal, Minister Vows to Subsidize Morning/Nighttime Vaccinations
  April 28, 2021

• Rebuild Vaccine Development System as National Security: CEFP Members
  April 27, 2021

• LDP Team Adopts Proposals to Push Japan-Made COVID-19 Vaccines, Urges Approval with Safety/Immunogenicity Studies
  April 27, 2021

• Japan Eyes Different Supply Routes for Non-Pfizer COVID-19 Vaccines: Kono
  April 26, 2021

• Don’t Take Vaccines If You Feel Ill: Safety Panels to Elderly
  April 26, 2021

• Japan PM Mulls Legal Revision on Trial Requirement for Vaccines
  April 26, 2021

• Olumiant Snags Japan Approval for COVID-19
  April 23, 2021

• MSD’s Recarbrio, Rinvoq’s Psoriasis Use Clears PAFSC Review; June Approval Likely
  April 22, 2021

• Major Modifications of CEA Scheme Difficult with Few Examples: Chuikyo
  April 22, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 148
• 149
• 150
• 151
• 152
• 153
• 154
• 155
• 156
• …
• Next ›
• 最終 »